EVO101 vs LT-002-158

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: IRAK4 · full Atopic Dermatitis pipeline

EVO101

Developed by Evommune

Phase 2 in Atopic Dermatitissmall molecule
Partial signal

NCT05579899 · Phase 2 · completed

The study was randomized, triple-blinded, vehicle-controlled, and included 119 participants, with the clinical EASI measure as its primary endpoint. The primary endpoint was not met: the mean EASI change at week 8 was larger with vehicle cream (-62.0%) than with EVO101 (-43.5%).

Reported efficacy

Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) (missed)

Result source: NCT05579899

LT-002-158

Developed by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Phase 2 in Atopic Dermatitistargeted protein degrader
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2028 · NCT07895615 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEVO101LT-002-158
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change-43.5% vs -62%+18.5 vs placebowk 8 · n 60NCT05579899—Not reported

EASI-75

EVO101
—Not reported
LT-002-158
—Not reported

IGA 0/1 with 2-point improvement

EVO101
—Not reported
LT-002-158
—Not reported

EASI-90

EVO101
—Not reported
LT-002-158
—Not reported

EASI, % change

EVO101
-43.5% vs -62%+18.5 vs placebowk 8 · n 60NCT05579899
LT-002-158
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

LT-002-158: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. EVO101: 4 of 4 rows · LT-002-158: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEVO101
Dropout rate
5%
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Discontinued due to AEs
0%
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Serious AEs
0%
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Most frequent reported AEs
application site pruritus 13.3% (placebo 20.7%)
application site pain 10% (placebo 12.1%)
application site erythema 6.7% (placebo 17.2%)
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

EVO101

EASI -43.5% (n=60) vs -62% (n=59) placebo @ 8wk
percent change · % of baseline
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
IGA 35.1% (n=57) vs 45.1% (n=51) placebo @ 8wk
responder rate · % of participants
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2 · converted to % from 20 Participants as posted
BSA -2.1% (n=57) vs -3.5% (n=51) placebo @ 8wk
absolute change · percentage points
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Pruritus -2.5 vs -3.5 placebo score @ 8wk
absolute change · score
NCT05579899 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EVO101's landscape · LT-002-158's landscape